TY - JOUR
T1 - Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
AU - Schettini, Francesco
AU - Giuliano, Mario
AU - Lambertini, Matteo
AU - Bartsch, Rupert
AU - PINATO, David James
AU - Onesti, Concetta Elisa
AU - Harbeck, Nadia
AU - Lüftner, Diana
AU - Rottey, Sylvie
AU - van Dam, Peter A.
AU - Zaman, Khalil
AU - Mustacchi, Giorgio
AU - Gligorov, Joseph
AU - Awada, Ahmad
AU - Campone, Mario
AU - Wildiers, Hans
AU - Gennari, Alessandra
AU - Tjan-Heijnen, Vivianne C. G.
AU - Cortes, Javier
AU - Locci, Mariavittoria
AU - Paris, Ida
AU - Mastro, Lucia Del
AU - Placido, Sabino De
AU - Martín, Miguel
AU - Jerusalem, Guy
AU - Venturini, Sergio
AU - Curigliano, Giuseppe
AU - Generali, Daniele
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non‐pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450–480 mg/m2. Following three pivotal first‐line phase III trials in HER2‐negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2‐negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms.
AB - Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non‐pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450–480 mg/m2. Following three pivotal first‐line phase III trials in HER2‐negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2‐negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms.
UR - https://iris.uniupo.it/handle/11579/128448
M3 - Article
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
ER -
